
|Articles|April 20, 2020
Ripple Science Announces Initiatives During COVID-19
Advertisement
Ripple Science has announced new initiatives to help clinical researchers continue their research during this uncertain time by giving research teams free access to Ripple for their first study. For those working on COVID-19 trials directly, the company is providing six-months of access free of charge.
For more information, click
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Beyond Patient Centricity: What Rare Disease Research Gets Right
2
What This Study Means for Sponsors Still Struggling to Justify RBQM at Scale
3
The Unquantified Value of RBQM: Reduced Rework, Data Integrity, and Inspection Readiness
4
ACT Brief: Time Savings as RBQM Value Driver, FDA Tightens Foreign Trial Oversight, and Trusted Research Environments Versus Flat Files
5




